spite
year
basic
clinic
research
rotavirus
follow
discoveri
rotavirus
continu
global
health
concern
children
rotaviru
member
reovirida
famili
virus
common
infecti
agent
underli
sever
diarrheal
diseas
respons
approxim
onethird
case
requir
rotaviru
enter
result
death
annual
children
less
accord
world
health
organ
although
licens
oral
live
attenu
rotaviru
vaccin
avail
intern
rotarix
rotateq
rotavirusmedi
childhood
fatal
occur
within
develop
nation
due
limit
access
vaccin
sanit
concern
insuffici
avail
routin
healthcar
clinic
manag
acut
rotaviru
enter
larg
consist
oral
rehydr
therapi
zinc
supplement
licens
antivir
therapi
approv
rotaviru
infect
rotavirus
also
caus
sever
diarrheal
diseas
young
anim
includ
livestock
speci
also
repres
consider
threat
global
livestock
health
potenti
sever
econom
consequ
increas
clariti
regard
relat
rotaviru
molecular
pathogenesi
pathophysiolog
could
help
inform
current
patient
care
modal
identif
key
molecular
determin
involv
pathophysiolog
sever
rotaviru
infect
may
also
assist
drug
discoveri
develop
strategi
end
consider
effort
past
decad
identifi
role
hostrotaviru
interact
rotaviru
pathogenesi
particular
mani
effort
focus
rotavirus
usurp
host
cell
innat
immun
respons
ubiquit
network
pattern
recognit
receptor
prr
rotavirus
capabl
suppress
interferon
ifn
respons
earli
stage
inde
prophylact
administr
ifn
restrict
rotaviru
replic
vitro
previou
investig
demonstr
rotaviru
infect
result
prrmediat
activ
suggest
viralcentr
mechan
exist
counteract
rotaviru
nonstructur
protein
mediat
degrad
multipl
interferon
regulatori
factor
irf
member
includ
also
suggest
inhibit
nuclear
transloc
transcript
factor
signal
transduc
activ
transcript
recent
investig
also
demonstr
may
also
downregul
innat
immun
respons
direct
interact
prr
downregul
retino
acidinduc
gene
rigi
like
addit
concert
effort
investig
rotavirusmedi
regul
host
cell
protein
translat
propos
modifi
intracellular
local
polyabind
protein
pabp
impair
interact
result
repress
host
translat
process
accentu
viral
interestingli
recent
work
halasz
et
al
demonstr
rotaviru
bindingentri
replic
increas
via
induct
integrin
express
phosphatidylinositol
depend
issu
virul
yin
et
al
provid
compel
evid
role
phosphatidylinositol
protein
kinas
b
akt
mechanist
target
rampamycin
mtor
signal
pathway
product
rotaviru
infect
identifi
downstream
signal
intermedi
may
repres
novel
antirotaviru
therapeut
author
use
vitro
cell
cultur
model
rotaviru
infect
simian
rotaviru
strain
use
tradit
cell
cultur
immort
colorect
epitheli
cell
human
primari
intestin
organoid
pharmacolog
inhibitor
pathway
prophylact
treatment
immort
cell
primari
organoid
potent
inhibitor
inhibit
total
viral
rna
infecti
viru
particl
product
although
result
suggest
could
import
target
futur
drug
develop
consider
author
assess
role
addit
signal
pathway
intermedi
rotaviru
infect
inhibit
mtor
shrna
nanomolar
concentr
rapamycin
sirolimusrapamun
licens
mtor
inhibitor
administ
prevent
organ
transplant
reject
result
significantli
reduc
rotaviru
infect
rapamycinmedi
inhibitori
effect
retain
follow
infect
patientderiv
rotaviru
strain
highlight
broad
import
mtor
product
rotaviru
infect
treatment
dual
inhibitor
also
inhibit
rotaviru
infect
primari
immort
cell
observ
build
previou
investig
bagchi
et
al
regard
import
signal
pathway
rotaviru
bagchi
colleagu
demonstr
rotaviru
infect
result
activ
signal
pathway
nonstructur
protein
depend
mechan
yin
et
al
provid
confirm
phenomenon
provid
novel
inform
regard
downstream
intermedi
within
signal
pathway
critic
product
rotaviru
infect
modul
signal
pathway
product
infect
demonstr
critic
broad
rang
virus
impact
global
health
divers
rang
viral
famili
includ
filovirida
ebola
viru
coronavirida
middl
east
respiratori
syndrom
coronaviru
poxvirida
monkeypox
viruscowpox
virusvaccinia
viru
arenavirida
lymphocyt
choriomening
viru
picornavirida
coxsackieviru
requir
activ
pathway
product
infect
prior
investig
demonstr
induct
autophagi
may
repres
earli
defens
mechan
within
infect
cell
viral
infect
postul
induct
autophagi
allow
host
cell
neutral
invad
pathogen
earli
infecti
cycl
activ
apoptot
mechan
within
infect
multipl
virus
includ
human
hepat
b
virusx
chikungunya
shown
induc
autophagi
infect
cell
recent
wu
et
al
demonstr
rotaviru
infect
result
autophagi
induct
intestin
gnotobiot
yin
colleagu
provid
accompani
mechanist
data
rotavirusinduc
autophagi
author
demonstr
silenc
eukaryot
translat
initi
factor
protein
result
signific
reduct
rotaviru
infect
demonstr
knockdown
immort
cell
delet
knockout
mous
embryon
fibroblastsmef
rapamycin
treatment
effect
rotaviru
infect
condit
contrast
rapamycin
treatment
inhibit
rotaviru
infect
follow
reconstitut
cell
build
observ
yin
et
al
demonstr
knockdown
chain
microtubuleassoci
autophagosom
marker
involv
earli
induct
autophagi
yin
colleagu
provid
clear
evid
central
role
signal
pathway
rotaviru
pathogenesi
modul
pathway
select
inhibit
pathway
intermedi
result
inhibit
viral
replic
induct
autophagi
intriguingli
author
investig
suggest
licens
kinas
inhibitor
target
pathway
could
potenti
repurpos
altern
therapeut
strategi
combat
rotaviru
enter
design
develop
novel
therapeut
includ
antiinfect
increasingli
impair
associ
time
cost
develop
move
novel
therapeut
preclin
phase
market
repurpos
licens
therapeut
altern
malign
includ
infecti
diseas
entic
altern
impedi
recent
support
strategi
nation
institut
health
center
advanc
translat
thu
repurpos
licens
kinas
inhibitor
novel
antiinfect
agent
appear
logic
approach
novemb
kinas
inhibitor
obtain
us
food
drug
administr
fda
licensur
continu
increas
number
variou
clinic
preclin
stage
support
administr
miltefosin
akt
inhibitor
grant
approv
use
antileishmani
investig
demonstr
pharmacolog
inhibit
signal
pathway
result
increas
surviv
lethal
model
ebola
viru
infect
mice
inhibit
mtor
rapamycin
everolimu
inhibit
middl
east
respiratori
syndrom
coronaviru
infect
yin
et
al
provid
compel
evid
futur
vivo
efficaci
studi
kinas
inhibitor
rotaviru
infect
model
broader
perspect
result
provid
justif
detail
investig
efficaci
select
inhibitor
target
signal
pathway
novel
antivir
therapeut
virus
impact
global
human
andor
livestock
health
